Goldman Sachs Group Inc Gemini Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.31 - $2.01 $22,466 - $34,471	-17,150 Reduced 46.81%	19,485 $32,000
Q3 2022 Nov 10, 2022	SELL	$1.31 - $2.01 $22,466 - $34,471	-17,150 Reduced 46.81%	19,485 $0
Q2 2022 May 14, 2024	BUY	$1.22 - $1.73 $44,694 - $63,378	36,635 New	36,635 $62,000
Q2 2022 Aug 15, 2022	BUY	$1.22 - $1.73 $19,882 - $28,193	16,297 Added 80.13%	36,635 $62,000
Q1 2022 May 16, 2022	SELL	$1.29 - $3.08 $67,647 - $161,515	-52,440 Reduced 72.05%	20,338 $28,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $138,280 - $231,432	57,858 Added 387.79%	72,778 $212,000
Q3 2021 Nov 10, 2021	BUY	$3.3 - $6.32 $49,236 - $94,294	14,920 New	14,920 $60,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.